louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03527524: Effect of Exercises on Pain, Functional Disability and Lumbar Stability in Patients With Low Back Pain
Official title: Effects of Core Stabilization Exercises With and Without Ball on Pain, Functional Disability and Level of Lumbar Stability in Patients With Non-specific Chronic Low Back Pain
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Exercise
Keywords: exercise
Lead sponsor: Mahidol University
Sponsor class: OTHER
First posted: 2018-05-17
Enrollment: 28
Sex: ALL
Minimum age (years): 20
Maximum age (years): 68
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The purposes of this study are to compare the effects of core stabilization exercises on pain intensity, functional disability and lumbar stability between using and not using the Swiss ball in patients with non-specific chronic low back pain.

Detailed description: For Patient Registries:

The participant was screened for inclusion criteria and was asked to sign the informed consent prior to participate. A randomized control trial was performed with participants randomly divided into one of the two treatment groups: core stabilization exercise with ball and core stabilization exercise without ball by using sealed envelopes.

Eligibility criteria: Inclusion Criteria:

1. Male and female with low back pain (LBP) \> 3 months
2. Body mass index (BMI) = 18-25 kg/m2
3. Non-specific LBP (pain at the lower lumbar between costal margin but not below gluteal fold)
4. Willing and able to perform exercise programs
5. No cognitive impairment
6. Age at least 19 years

Exclusion Criteria:

1. Having experiences in the core stabilization exercise and Swiss ball exercises
2. Past history of back and abdomen surgery
3. Recent fractures of spine, hip or lower limb
4. Current use of steroids or any other drugs for resolving back pain
5. Red flags (fractures, cancer, infection, cauda equine syndrome)
6. Pregnancy
7. Neuromuscular or respiratory disorders
8. Rheumatologic disorders
9. Hip and knee stiffness
10. Pain intensity \> 60 of 100 mm assessed by the VAS

Primary outcomes:
measure: Pain scale
timeFrame: 4 weeks
Secondary outcomes:
measure: Questionnaire scores of functional disability measure
timeFrame: 4 weeks
measure: Levels of lumbar stability
timeFrame: 4 weeks
Other outcomes:
Locations:
Study officials:
affiliation: Mahidol University
name: Apinkarn Jaroenlarp, MSc
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03560024: The Effect of PACAP27 on the Extra- and Intracerebral Arteries Assessed by Magnetic Resonance Angiography (MRA) on Healthy Volunteers
Official title: The Effect of PACAP27 on the Extra- and Intracerebral Arteries Assessed by MRA on Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Headache, Migraine
Lead sponsor: Danish Headache Center
Sponsor class: OTHER
First posted: 2018-06-18
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: 18 healthy volunteers will receive PACAP27 or placebo. All Data will also be analyses blinded.
Primary purpose: OTHER

Brief summary: Studying Pituitary adenylate cyclase-activating peptide 27 (PACAP27) effects on extra- and intracerebral arteries assessed by MRA on healthy volunteers.

Detailed description: PACAP neuropeptide, which belongs to the vasoactive intestinal polypeptide (VIP)/glucagon/secretin family. PACAP exists in two forms: Studying Pituitary adenylate cyclase-activating peptide 38 (PACAP38), which consists of 38 amino acids and PACAP27 which contains 27 amino acids at its N-terminus. PACAP38 is implicated in migraine pathophysiology however PACAP27 is not studied well. Therefore, the investigators will study PACAP27's effect on extra- and intracerebral arteries assessed by MRA on healthy volunteers.

Eligibility criteria: Inclusion Criteria:

* Healthy volunteers
* Aged 18-50
* 50-100 kg

Exclusion Criteria:

* Tension type headache more than 5 dag /month
* Other primary headaches
* Daily medication except contraceptives
* Drug taken within 4 times the half-life for the specific drug except contraceptives
* Pregnant or lactating women
* Exposure to radiation within the last year
* Headache within the last 24 hours before start of trial
* Hypertension
* Hypotension
* Respiratory or cardiac disease
* Primary relatives with current or previous migraine

Primary outcomes:
measure: Dilation of extra- and intracerebral arteries
timeFrame: 0-290 min
Secondary outcomes:
measure: Headache
timeFrame: 0 to 24 hours
Other outcomes:
Locations:
city: Glostrup
country: Denmark
facility: Danish Headache Center
Study officials:
References:
Clinical trial NCT06586424: The Prognostic Value of Anion Gap in Predicting Major Adverse Cardiovascular Events Among Patients With ST-Segment Elevation Myocardial Infarction
Official title: The Prognostic Value of Anion Gap in Predicting Major Adverse Cardiovascular Events Among Patients With ST-Segment Elevation Myocardial Infarction
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: ST-segment Elevation Myocardial Infarction (STEMI)
Keywords: anion gap
major adverse cardiovascular events
st-segment elevation myocardial infarction
Lead sponsor: Universitas Diponegoro
Sponsor class: OTHER
First posted: 2024-09-19
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patient with ST-segment elevation myocardial infarction who underwent PPCI

Brief summary: This study aims to evaluate the prognostic value of the anion gap in predicting major adverse cardiovascular events among patients with ST-segment elevation myocardial infarction. Researchers will collect information based on hospital registry as secondary data of in patient who had diagnosed as ST-segment elevation myocardial infarction and underwent primary percutaneous coronary intervention. The data consist of demographic data, clinical presentation, laboratory, and angiography result were collected from hospital registry by reviewing medical record. Then, the data was analyzed by using IBM SPSS Statistics v26.


Eligibility criteria: Inclusion Criteria:

* Adults with 18 - 70 years old with diagnosis of STEMI who underwent PPCI

Exclusion Criteria:

* History of heart failure due to any causes
* Cardiogenic shock before PPCI
* Any infection at the time of presentation
* Pregnant woman
* Other causes of high anion gap levels such as chronic kidney disease, metabolic acidosis, etc

Primary outcomes:
measure: Major Adverse Cardiovascular Events (MACE)
timeFrame: During hospitalization, up to 1 weeks
Secondary outcomes:
measure: Incidence of mortality
timeFrame: During hospitalization, up to 1 weeks
measure: Incidence of reinfarction
timeFrame: During hospitalization, up to 1 weeks
measure: Incidence of stroke
timeFrame: During hospitalization, up to 1 weeks
measure: Incidence of lethal arrhythmia
timeFrame: During hospitalization, up to 1 weeks
measure: Incidence of acute lung oedema
timeFrame: During hospitalization, up to 1 weeks
measure: Incidence of cardiogenic shock
timeFrame: During hospitalization, up to 1 weeks
Other outcomes:
Locations:
city: Semarang
country: Indonesia
facility: Dr. Kariadi Central General Hospital
state: Central Of Java
Study officials:
References:
Clinical trial NCT01329224: The Antiaggregation Monitoring (TAM) Registry
Official title: Acetylsalicylic Acid in Outpatient Practice - Results From The Antiaggregation Monitoring (TAM) Registry
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Aspirin Causing Adverse Effects in Therapeutic Use
Keywords: acetylsalicylic acid resistance
Lead sponsor: University Hospital Freiburg
Sponsor class: OTHER
First posted: 2011-04-05
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All consecutive patients under chronic ASA treatment seen at our outpatient clinic

Brief summary: The purpose of this study is to investigate the incidence of acetylsalicylic acid resistance (ASA-R) among patients under chronic acetylsalicylic acid(ASA) treatment seen at our outpatient clinic.

Detailed description: Acetylsalicylic acid (ASA) resistance (R) is best defined as an ineffective inhibition of the platelet cyclooxygenase (COX)-1 pathway, and has been reported in 1 to 61 % of patients treated with ASA. Impaired response to ASA has been associated with an increased risk of ischemic events in patients with known coronary artery disease. We sought to investigate the incidence of ASA-R in clinical practice.

All consecutive patients under chronic ASA treatment (100mg/d) seen at our outpatient clinic were systematically included in the registry. All patients were on acetylsalicylic acid for CAD for at least 1 month. Patients were informed of ASA testing at start of consultation in the outpatient clinic. Eligible patients provided written informed consent. Peripheral venous blood samples were analyzed using the whole blood impedance platelet aggregometry Multiplate analyzer. The Multiplate analyzer device allows to measure platelet aggregation by the attachment of platelets to two silver coated copper electrodes leading to a rise of electrical resistance in the sample. The measurements are expressed as arbitrary aggregation units (AU) and the manufacturers defined cutoffs were used: normal values were 76-136 AU, partial antiaggregation was defined as ASA values between 31 and 75 AU and complete antiaggregation was defined as ASA values \< 31 AU.

Eligibility criteria: Inclusion Criteria:

* patients under chronic ASA treatment for more then one month

Exclusion Criteria:

* concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs)
* thrombocytopenia
* thrombocytosis
* age \<18 years

Primary outcomes:
measure: Whole blood impedance platelet aggregometry to assess acetylsalicylic acid resistance rates
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Fribourg
country: Switzerland
facility: Service de Cardiologie, Hôpital Cantonal Fribourg
state: FR
Study officials:
affiliation: Fribourg University
name: Stéphane Cook, Prof
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01638624: The Effect of Propofol Infusion on Total Antioxidant Status During Tourniquet-Induced Ischemia-Reperfusion Injury
Official title: The Effect of Propofol Infusion on Total Antioxidant Status During Tourniquet-Induced Ischemia-Reperfusion Injury in Total Knee Arthroplasty
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Total Knee Arthroplasty
Tourniquet-Induced Ischemia-Reperfusion Injury
Keywords: Propofol
antioxidant capacity
total knee arthroplasty
Propofol,antioxidant
Lead sponsor: Diskapi Teaching and Research Hospital
Sponsor class: OTHER
First posted: 2012-07-12
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The release of tourniquet produces reactive oxygen species which can cause injury. Propofol is chemically similar to phenol-based free radical scavengers.

Plasma total antioxidant capacity is a well-established marker of the overall protective effect of antioxidants in body fluids.The aim of the study is to investigate the effects of propofol on ischemia-reperfusion injury in total knee arthroplasty (TKA).


Eligibility criteria: Inclusion Criteria:

* ASA I-II physical status
* Unilateral total knee arthroplasty
* Age 18 years to 80 years

Exclusion Criteria:

* Severe central nervous system disorders
* Severe cardiopulmonary,renal,metabolic, or hepatic disease,
* Blood volume deficits,
* Coagulopathy,
* Allergy to local anesthetics,
* Peripheral neuropathies,
* Body mass index \> 35,
* History of antioxidant drug use

Primary outcomes:
measure: The perioperative alternation of the venous blood total antioxidant capacity levels of the arms
timeFrame: T1,T2,T3
Secondary outcomes:
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Ministry of health Diskapi Yıldirim Beyazit Training and Research Hospital Anesthesiology and Biochemistry Clinics
Study officials:
affiliation: Ministry of health Diskapi Yıldirim Beyazit Training and Research Hospital Anesthesiology Clinic
name: Derya Özkan, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Ministry of health Diskapi Yıldirim Beyazit Training and Research Hospital Anesthesiology Clinic
name: Taylan Akkaya, MD
role: STUDY_CHAIR
affiliation: Ministry of health Diskapi Yıldirim Beyazit Training and Research Hospital Biochemistry Clinic
name: Ali Yalcindag, MD
role: STUDY_CHAIR
affiliation: Ministry of health Diskapi Yıldirim Beyazit Training and Research Hospital Biochemistry Clinic
name: Tuba Hanci, MD
role: STUDY_CHAIR
affiliation: Ministry of health Diskapi Yıldirim Beyazit Training and Research Hospital Anesthesiology Clinic
name: Haluk Gümüs, MD
role: STUDY_CHAIR
affiliation: Ministry of health Diskapi Yıldirim Beyazit Training and Research Hospital Biochemistry Clinic
name: Namik Delibas, MD
role: STUDY_CHAIR
affiliation: Ministry of health Diskapi Yıldirim Beyazit Training and Research Hospital Orthopedics Clinic
name: Emel Gönen, Consultant
role: STUDY_CHAIR
References:
Clinical trial NCT00472524: Cycloplegic Delivery Investigation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Lead sponsor: Ohio State University
Sponsor class: OTHER
First posted: 2007-05-11
Enrollment: 50
Sex: ALL
Minimum age (years): 8
Maximum age (years): 30
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The goal of this study is to compare the effectiveness of the administration of sequential drops, a combination drop and a combination spray for producing mydriasis and cycloplegia.


Eligibility criteria: Inclusion Criteria:

* patients ages 8 to 30 with best corrected acuity of 20/30 or better in both eyes at distance and near will be recruited.

Exclusion Criteria:

* vision not correctable to 20/30 or better

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Ohio State University
name: Marjean Kulp, OD, MS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02276924: Diagnostic Relevance of Laser Confocal Microscopy for the Screening of Upper Urinary Tract Tumors
Official title: Diagnostic Relevance of Laser Confocal Microscopy During Reno-ureteroscopy in the Context of the Screening and Follow-up of Upper Urinary Tract Tumors
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hematuria
Nephrolithiasis
Cancer of Urinary Tract
Ureteropelvic Junction Obstruction
Keywords: Laser Confocal Microscopy
Superior Urinary Tract Tumors
Lead sponsor: Lille Catholic University
Sponsor class: OTHER
First posted: 2014-10-28
Enrollment: 29
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Upper Urinary Tract Tumors have an incidence of 1 to 2 cases for 100 000 persons per year. The standard treatment for these tumors is the ablation of the kidney, ureter and a part of the bladder surrounding the ureteral orifice. The development of new diagnosis and treatment techniques through natural routes opens the possibility to use conservative treatments. The investigators hypothesis is that during a reno-ureteroscopy, laser confocal microscopy will allow the discrimination between normal and pathologic urothelium by microscopic analysis. This will prevent the systematic use of biopsies which are often difficult and iatrogenic.

Detailed description: The objective of the present study is to assess contribution of laser confocal microscopy in diagnosing of upper urinary tract tumors during a reno-uteroscopy compared to analysing of architectural elements (vascular characteristics, organization) and cellular (morphology, cohesion, border).

Eligibility criteria: Inclusion Criteria:

* Any legally adult fully informed patient who consent to participate to the study
* Patient followed by the Urology Department
* Indication for a diagnosis or treatment reno-ureteroscopy
* Coverage of the social insurance

Exclusion Criteria:

* Minor Patient
* Pregnancy or breast feeding
* Concomitant treatment (for example beta-blocker)
* Contra-indication to general anaesthesia
* Hypersensitivity to sodium fluorescein
* Medical history of cardio-pulmonary disease (myocardial infarction, cardiovascular event, bronchospasm ...) due to fluorescein instillation
* Medical history of asthma or allergy due to fluorescein instillation

Primary outcomes:
measure: Diagnostic relevance of laser confocal microscopy compared to the cytological and histological data, during reno-ureteroscopy according to Chang's reference criteria
timeFrame: 24 months
Secondary outcomes:
measure: Inter- and intra-observer diagnostic concordance
timeFrame: 24 months
measure: Surgery duration
timeFrame: 24 months
measure: Reference atlas
timeFrame: 24 months
Other outcomes:
Locations:
city: Lille
country: France
facility: Groupement des Hôpitaux de l'Institut Catholique de Lille
state: Nord Pas-de-Calais
Study officials:
affiliation: Groupement des Hôpitaux de l'Institut Catholique de Lille
name: Jean-Louis Bonnal, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00806624: DU-176b Phase 2 Dose Finding Study in Subjects With Non-valvular Atrial Fibrillation
Official title: A Phase 2, Randomized, Parallel Group, Multi-Center, Multi-National Study for the Evaluation of Safety and Efficacy of Two Fixed Dosages of DU-176b in Subjects With Non-Valvular Atrial Fibrillation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Atrial Fibrillation
Stroke
Lead sponsor: Daiichi Sankyo
Sponsor class: INDUSTRY
First posted: 2008-12-11
Enrollment: 234
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study will be conducted in male and female subjects aged 18 to 80 years, inclusive, with non-valvular AF and a CHADS2 Score of at least 1. Subjects will be treated on an outpatient basis. The subjects will be allocated randomly to the open-label warfarin or any double-blind DU-176b dosages. DU-176b will be administered orally for 12 weeks at two fixed doses. Warfarin will be used as active control. Warfarin dosing will be managed and monitored by the Investigator with the dose adjusted to achieve an INR of 2.0 to 3.0, inclusive. The primary endpoints are incidence of major, clinically relevant non-major and minor bleeding events (all bleeding).


Eligibility criteria: Inclusion Criteria:

* Male or female subjects 18 to 80 years of age
* Non-valvular AF supported by abnormal ECG documented for two times (interval of more than 1 week) within 6 months prior to randomization.
* CHADS2 Score of at least 1.

Exclusion Criteria:

* Subjects with mitral valve disease
* Subjects with previous valvular heart surgery
* Contraindication for anticoagulants
* Conditions associated with high risk of bleeding
* Acute coronary syndromes (ACS), percutaneous coronary intervention (PCI), MI, stroke, transient ischemic attack (TIA) or coronary artery/cardiac/other major surgery within the previous 30 days
* Active infective endocarditis or life-expectancy \< 12 months

Primary outcomes:
measure: Incidence of All Bleeding
timeFrame: 6 months
Secondary outcomes:
measure: Evaluation of Incidence of Major Adverse Cardiovascular Events: Stroke, Systemic Embolic Event, Myocardial Infarction, Cardiovascular Death, and Hospitalization for Any Cardiac Condition
timeFrame: 6 months
measure: Evaluation of Effects on Biomarkers of Thrombus Formation
timeFrame: 6 months
measure: Evaluation of Plasma Concentration of DU-176
timeFrame: 6 months
measure: Evaluation of Effects on Pharmacodynamic Biomarkers
timeFrame: 6 months
measure: Evaluation of All Clinical and Laboratory Safety Data.
timeFrame: 6 months
Other outcomes:
Locations:
city: Hong-Kong
country: China
city: Seoul
country: Korea, Republic of
city: Singapore
country: Singapore
city: Taipei
country: Taiwan
Study officials:
References:
Clinical trial NCT04980924: Epidemiology and Clinical Course of Pulmonary Embolism During and After Hospitalisation
Official title: Pulmonary Embolism Registry
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pulmonary Embolism
Lead sponsor: Centre Hospitalier Universitaire de Nice
Sponsor class: OTHER
First posted: 2021-07-28
Enrollment: 547
Sex: ALL
Minimum age (years): 18
Maximum age (years): 110
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All pulmonary embolisms hospitalised in our department

Brief summary: This survey will allow to identify PE prognostic, but also long-term complications, i.e. recurrence rate, on-treatment bleedings, deep-vein thrombosis sequella, pulmonary hypertension rate, and chronic pulmonary disease rate without PH. This database should help us identify risk-factors for each event.


Eligibility criteria: Inclusion Criteria:

* All pulmonary embolisms hospitalised in Nice hospital.
* acceptation to enter in the cohorte survey

Exclusion Criteria:

-

Primary outcomes:
measure: Reccurence
timeFrame: 10 years
Secondary outcomes:
measure: Pulmonary hypertension
timeFrame: 10 years
measure: Chronic pulmonary disease without hypertension
timeFrame: 10 years
Other outcomes:
Locations:
city: Nice
country: France
facility: Nice University Hospital
Study officials:
References:
citation: Ferrari E, Fourrier E, Asarisi F, Heme N, Redjimi N, Berkane N, Labbaoui M, Breittmayer JP, Bun SS, Moceri P, Squara F. Is pulmonary embolism recurrence linked with the severity of the first event? A French retrospective cohort study. BMJ Open. 2021 Sep 29;11(9):e050910. doi: 10.1136/bmjopen-2021-050910.